Takeda Pharmaceutical Files 6-K Report

Ticker: TKPHF · Form: 6-K · Filed: May 29, 2024 · CIK: 1395064

Takeda Pharmaceutical Co Ltd 6-K Filing Summary
FieldDetail
CompanyTakeda Pharmaceutical Co Ltd (TKPHF)
Form Type6-K
Filed DateMay 29, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: regulatory-filing, foreign-private-issuer

TL;DR

Takeda filed a 6-K, just a standard update from Tokyo HQ.

AI Summary

Takeda Pharmaceutical Company Limited filed a Form 6-K on May 29, 2024, reporting its status as a foreign private issuer. The filing indicates Takeda's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan.

Why It Matters

This filing is a routine report for foreign private issuers, providing an update on Takeda's corporate information and regulatory status in the U.S.

Risk Assessment

Risk Level: low — This is a routine administrative filing and does not contain new financial or operational information that would typically impact risk.

Key Players & Entities

  • Takeda Pharmaceutical Company Limited (company) — Filer of the 6-K report
  • 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan (location) — Principal executive offices

FAQ

What type of filing is this Form 6-K?

This Form 6-K is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.

When was this Form 6-K filed?

This Form 6-K was filed on May 29, 2024.

Where are Takeda Pharmaceutical Company Limited's principal executive offices located?

Takeda Pharmaceutical Company Limited's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan.

Does Takeda file its annual reports under Form 20-F or 40-F?

Takeda indicates it files its annual reports under Form 20-F.

What is the Commission File Number for Takeda Pharmaceutical Company Limited?

The Commission File Number for Takeda Pharmaceutical Company Limited is 001-38757.

Filing Stats: 198 words · 1 min read · ~1 pages · Grade level 15.4 · Accepted 2024-05-29 06:24:59

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TAKEDA PHARMACEUTICAL COMPANY LIMITED Date May 29, 2024 By s Norimasa Takeda Norimasa Takeda Chief Accounting Officer and Corporate Controller

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.